Home › Funds › State Street › State Street SPDR S&P Biotech ETF
Fund family: State Street · Filed by SPDR SERIES TRUST (CIK 1064642) · SEC series S000010018
Ticker: XBI (C000027706)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 495 with, 488 against, 0 abstentions (not counted as with management). Shareholder proposals: 0 FOR, 6 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as State Street’s manager page (773,265 ballot items across 134 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | State Street | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 89.1% | 953 | 89.7% | 592,191 |
| Backed environmental and social shareholder proposals at US companies | n/a | 2 | 6.8% | 3,767 |
Each ballot item this fund voted is set against the votes of the other State Street funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted the same way as most State Street funds on all 896 items where a comparison was possible.
The same votes as “with management” above, by the sector of the company voted on. 96.1% of this fund’s 983 such votes could be given a sector; the other 38 (3.9%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 945 | 477 | 50.5% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 588 | 286 |
| Say-on-Pay | 151 | 77 |
| Audit-related | 140 | 78 |
| Compensation | 74 | 38 |
| Corporate Governance | 27 | 2 |
| Capital Structure | 18 | 6 |
| Extraordinary Transactions | 6 | 0 |
| Environment or Climate | 1 | 1 |
| Other Social Issues | 1 | 0 |
| Shareholder Rights and Defenses | 1 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Moderna, Inc. | November 12, 2025 | $720M | 2 | 0 |
| Moderna, Inc. | May 6, 2026 | $557M | 5 | 2 |
| Kodiak Sciences Inc. | June 2, 2026 | $148M | 5 | 3 |
| Halozyme Therapeutics, Inc. | May 5, 2026 | $147M | 4 | 1 |
| Revolution Medicines, Inc. | June 18, 2026 | $146M | 4 | 3 |
| Travere Therapeutics, Inc. | May 19, 2026 | $144M | 14 | 6 |
| Natera, Inc. | June 11, 2026 | $141M | 8 | 3 |
| Amgen Inc. | May 19, 2026 | $140M | 15 | 5 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 6, 2026 | Moderna, Inc. | To approve, on a non-binding, advisory basis, the compensation of our named executive officers. | For | Against |
| May 6, 2026 | Moderna, Inc. | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2026. | For | Against |
| June 2, 2026 | Kodiak Sciences Inc. | Elect three Class II directors nominated by our board and named in this proxy statement: Bassil I. Dahiyat, Ph.D. | For | Against |
| June 2, 2026 | Kodiak Sciences Inc. | Approve, on an advisory basis, the compensation of Kodiak's named executive officers, as disclosed in the proxy statement. | For | Against |
| May 5, 2026 | Halozyme Therapeutics, Inc. | To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. | For | Against |
| June 18, 2026 | Revolution Medicines, Inc. | To elect two Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until his successor is elected: Mark A. Goldsmith, M.D., Ph.D. | For | Against |
| June 18, 2026 | Revolution Medicines, Inc. | To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026; and | For | Against |
| May 19, 2026 | Travere Therapeutics, Inc. | To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year. ELECTION OF DIRECTORS: Roy Baynes | For | Against |
| May 19, 2026 | Travere Therapeutics, Inc. | To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year. ELECTION OF DIRECTORS: Timothy Coughlin | For | Against |
| June 11, 2026 | Natera, Inc. | To elect three directors named in the proxy statement accompanying this notice to serve as Class II directors until the annual meeting of stockholders held in 2029 and until their successors are duly elected and qualified, and to elect one director named in the proxy statement accompanying this notice to serve as a Class I director until the annual meeting of stockholders held in 2028 and until his successor is duly elected and qualified. Class II Nominees: Jonathan Sheena | For | Against |
| June 11, 2026 | Natera, Inc. | To ratify the appointment of Ernst & Young LLP as Natera, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2026. | For | Against |
| May 19, 2026 | Amgen Inc. | To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Robert A. Bradway | For | Against |
Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.
1,007 ballot items at 147 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, State Street SPDR S&P Biotech ETF (XBI) voted at 147 shareholder meetings of 144 companies, on 1,007 ballot items in all. Where management made a recommendation, the fund followed it on 50.4% of the items and voted against it 488 times. Its most frequent area of disagreement was director elections (286 of its votes against management). It voted on 6 shareholder proposals. It voted FOR the board's own proposals less often than State Street's funds as a whole (89.1% against 89.7%). It voted the same way as most State Street funds on every item where a comparison was possible. 1 of its meetings was contested.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of State Street’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.